{"generic":"Micafungin Sodium","drugs":["Micafungin Sodium","Mycamine"],"mono":{"0":{"id":"jwcgs0","title":"Generic Names","mono":"Micafungin Sodium"},"1":{"id":"jwcgs1","title":"Dosing and Indications","sub":[{"id":"jwcgs1b4","title":"Adult Dosing","mono":"<ul><li><b>Aspergillosis, Invasive:<\/b> (salvage therapy) 100 to 150 mg\/day IV; optimal dose not established<\/li><li><b>Aspergillosis, Invasive, high-risk patients; Prophylaxis:<\/b> (salvage therapy) 50 mg\/day IV<\/li><li><b>Candida endophthalmitis:<\/b> (alternative therapy) 100 mg\/day IV for at least 4 to 6 weeks<\/li><li><b>Candidemia:<\/b> (primary therapy) 100 mg\/day IV infusion over 1 hour; mean duration of therapy (clinical studies), 15 days (range, 10 to 47 days)<\/li><li><b>Candidiasis, Cardiovascular system infection:<\/b> 100 to 150 mg\/day IV<\/li><li><b>Candidiasis, Osteoarticular infection:<\/b> (alternative therapy) 100 mg\/day IV for at least 2 weeks, followed by fluconazole therapy<\/li><li><b>Candidiasis of the esophagus:<\/b> 150 mg\/day IV infusion over 1 hour; mean duration of therapy (clinical studies), 15 days (range 10 to 30 days)<\/li><li><b>Candidiasis of the esophagus:<\/b> (alternative therapy) 100 mg\/day IV for 14 to 21 days (guideline dosing)<\/li><li><b>Candidiasis of the esophagus - HIV infection:<\/b> 150 mg\/day IV infusion over 1 hour; mean duration of therapy (clinical studies), 15 days (range, 10 to 30 days)  OR 14 to 21 days (guideline dosing)<\/li><li><b>Disseminated candidiasis:<\/b> 100 mg\/day IV infusion over 1 hour; mean duration of therapy (clinical studies), 15 days (range, 10 to 47 days)<\/li><li><b>Disseminated candidiasis, chronic:<\/b> (alternative therapy) 100 mg\/day IV for 1 to 2 weeks, followed by oral fluconazole therapy when clinically stable<\/li><li><b>Disseminated candidiasis, Hematopoietic Stem Cell Transplantation; Prophylaxis:<\/b> (primary therapy) 50 mg\/day IV infusion over 1 hour; mean duration for prophylaxis (clinical studies), 19 days (range, 6 to 51 days)<\/li><li><b>Empirical antifungal therapy, Suspected candidiasis in nonneutropenic patients:<\/b> (primary therapy) 100 mg\/day IV until cultures and\/or serodiagnostic tests are negative<\/li><li><b>HIV infection - Oropharyngeal candidiasis:<\/b> (fluconazole-refractory) 150 mg IV daily<\/li><li><b>Oropharyngeal candidiasis:<\/b> (alternative therapy) 100 mg\/day IV<\/li><li><b>Pulmonary aspergillosis, Chronic (cavitary or necrotizing):<\/b> (salvage therapy) 100 to 150 mg\/day IV (optimal dose not established)<\/li><\/ul>"},{"id":"jwcgs1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness not established in pediatric patients younger than 4 months<\/li><li><b>Candidemia:<\/b> 2 mg\/kg IV infusion over 1 hour once daily; MAX 100 mg\/day<\/li><li><b>Candidiasis of the esophagus:<\/b> (30 kg or less) 3 mg\/kg IV infusion over 1 hour once daily<\/li><li><b>Candidiasis of the esophagus:<\/b> (greater than 30 kg) 2.5 mg\/kg IV infusion over 1 hour once daily; MAX 150 mg\/day<\/li><li><b>Disseminated candidiasis:<\/b> 2 mg\/kg IV infusion over 1 hour once daily; MAX 100 mg\/day<\/li><li><b>Disseminated candidiasis, Hematopoietic Stem Cell Transplantation; Prophylaxis:<\/b> 1 mg\/kg IV infused over 1 hour once daily; MAX 50 mg\/day<\/li><\/ul>"},{"id":"jwcgs1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dosage adjustment necessary<\/li><li><b>hepatic impairment (mild, moderate, or severe):<\/b> no dosage adjustment necessary<\/li><li><b>geriatric:<\/b> no dosage adjustment necessary<\/li><li><b>hemodialysis:<\/b> supplemental dosing is not necessary<\/li><\/ul>"},{"id":"jwcgs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Candidemia<\/li><li>Candidiasis of the esophagus<\/li><li>Candidiasis of the esophagus - HIV infection<\/li><li>Disseminated candidiasis<\/li><li>Disseminated candidiasis, Hematopoietic Stem Cell Transplantation; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Aspergillosis, Invasive<\/li><li>Aspergillosis, Invasive, high-risk patients; Prophylaxis<\/li><li>Candida endophthalmitis<\/li><li>Candidiasis, Cardiovascular system infection<\/li><li>Candidiasis, Osteoarticular infection<\/li><li>Disseminated candidiasis, chronic<\/li><li>Empirical antifungal therapy, Suspected candidiasis in nonneutropenic patients<\/li><li>HIV infection - Oropharyngeal candidiasis<\/li><li>Invasive fungal infection; Prophylaxis<\/li><li>Oropharyngeal candidiasis<\/li><li>Pulmonary aspergillosis, Chronic (cavitary or necrotizing)<\/li><\/ul>"}]},"3":{"id":"jwcgs3","title":"Contraindications\/Warnings","sub":[{"id":"jwcgs3b9","title":"Contraindications","mono":"known hypersensitivity to micafungin, any components of the product, or other echinocandins <br\/>"},{"id":"jwcgs3b10","title":"Precautions","mono":"<ul><li>hemolytic anemia and significant hemolysis (including acute intravascular hemolysis) have been reported<\/li><li>hepatic abnormalities (eg, liver function test (LFT) abnormalities, hepatic dysfunction, hepatitis, and hepatic failure) have occurred; patients on multiple concomitant medications with serious underlying medical conditions may be at increased risk; monitoring recommended in patients who develop abnormal LFTs<\/li><li>hypersensitivity reactions, including anaphylaxis and shock, have been reported<\/li><li>renal dysfunction (eg, BUN or creatinine elevations, acute renal failure) has occurred; monitoring recommended in patients who develop abnormal renal function tests<\/li><\/ul>"},{"id":"jwcgs3b11","title":"Pregnancy Category","mono":"Micafungin: C (FDA)<br\/>"},{"id":"jwcgs3b12","title":"Breast Feeding","mono":"Micafungin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jwcgs4","title":"Drug Interactions","sub":{"2":{"id":"jwcgs4b15","title":"Moderate","mono":"<ul><li>Itraconazole (probable)<\/li><li>Nifedipine (probable)<\/li><li>Sirolimus (probable)<\/li><\/ul>"}}},"5":{"id":"jwcgs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (treatment, 7% to 13%; prophylaxis, 51% to 77%), Nausea (treatment, 7% to 10%; prophylaxis, 70% to 71%), Vomiting (treatment, 7% to 18%; prophylaxis, 65% to 66%)<\/li><li><b>Hematologic:<\/b>Thrombocytopenia (treatment, 9%; prophylaxis, 72% to 75%)<\/li><li><b>Neurologic:<\/b>Headache (treatment, 9%; prophylaxis, 44%)<\/li><li><b>Other:<\/b>Fever (treatment, 7% to 13%; prophylaxis, 61%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Atrial fibrillation (treatment, 3% to 5%), Cardiac arrest (less than 5%), Myocardial infarction (less than 5%), Pericardial effusion (less than 5%)<\/li><li><b>Hematologic:<\/b>Anemia (treatment, 18%; prophylaxis, 51%), Hemolysis, Hemolytic anemia, Intravascular hemolysis<\/li><li><b>Hepatic:<\/b>Hepatitis, Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Encephalopathy (less than 5%), Intracranial hemorrhage (less than 5%), Seizure (less than 5%)<\/li><li><b>Renal:<\/b>Acute renal failure, Renal impairment, acute<\/li><\/ul>"},"6":{"id":"jwcgs6","title":"Drug Name Info","sub":{"0":{"id":"jwcgs6b17","title":"US Trade Names","mono":"Mycamine<br\/>"},"2":{"id":"jwcgs6b19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Echinocandin<\/li><li>Glucan Synthesis Inhibitor<\/li><\/ul>"},"3":{"id":"jwcgs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jwcgs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jwcgs7","title":"Mechanism Of Action","mono":"Micafungin sodium is a semisynthetic lipopeptide (echinocandin) antifungal agent, synthesized by a chemical modification of a fermentation product of Coleophoma empetri F-11899, that inhibits the synthesis of 1,3 beta-D-glucan, a fundamental constituent of fungal cell walls.<br\/>"},"8":{"id":"jwcgs8","title":"Pharmacokinetics","sub":[{"id":"jwcgs8b23","title":"Absorption","mono":"<ul><li>Tmax, IV, premature infants: 1.2 hours<\/li><li>Tmax, IV, pediatrics: 0.84 to 2.01 hours<\/li><li>Tmax, IV, adult lung transplant patients: 4 hours<\/li><\/ul>"},{"id":"jwcgs8b24","title":"Distribution","mono":"<ul><li>Vd, adults: 0.39 L\/kg<\/li><li>Vd, premature neonates: 0.39 to 0.76 L\/kg<\/li><li>Protein binding, Albumin: more than 99%<\/li><\/ul>"},{"id":"jwcgs8b25","title":"Metabolism","mono":"<ul><li>Hepatic: P450 CYP3A, arylsulfatase, and catechol-O-methyltransferase, hydroxylation<\/li><li>Metabolites: M-1 (catechol form), M-2 (methoxy form). and M-5<\/li><\/ul>"},{"id":"jwcgs8b26","title":"Excretion","mono":"<ul><li>Bile: approximately 40% (drug and metabolites)<\/li><li>Fecal: 71%<\/li><li>Renal: 15% or less unchanged<\/li><li>Dialyzable: No<\/li><li>Total body clearance: adults, 0.204 to 0.301 mL\/min\/kg<\/li><li>Total body clearance: pediatrics with weight 30 kg or less, 0.328 mL\/min\/kg; weight greater than 30 kg, 0.241 mL\/min\/kg<\/li><li>Total body clearance, pediatrics: 28.52 to 42.72 mL\/hr\/kg<\/li><li>Total body clearance: premature neonates, multiple dose, 89 mL\/hr\/kg (1 mg\/kg\/day); 0.4 mL\/min\/kg (7 mg\/kg\/day); 0.6 mL\/min\/kg (10 mg\/kg\/day)<\/li><\/ul>"},{"id":"jwcgs8b27","title":"Elimination Half Life","mono":"<ul><li>Adults, 10.7 to 17.2 hours<\/li><li>Premature neonates, 5.5 to 11 hours<\/li><li>Pediatrics patients aged 4 months to 16 years,12.5 hours (30 kg or less); 13.6 hours (greater than 30 kg)<\/li><li>Pediatric patients aged 2 to 17 years, 12 to 21 hours; less than 5 years, 10.13; 5 years and older, 13.81 hours<\/li><\/ul>"}]},"9":{"id":"jwcgs9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>add 5 mL D5W or NS without bacteriostatic agent to each 50-mg or 100-mg vial to yield a concentration of 10 mg\/mL or 20 mg\/mL, respectively; gently swirl vial, do not vigorously shake vial during reconstitution<\/li><li>(adult) add appropriate volume of reconstituted dose to 100 mL NS or D5W<\/li><li>(pediatric) withdraw appropriate volume of reconstituted solution from vial based on calculation of required dose (ie, pediatric dose [mg\/kg] x weight of patient [kg]) divided by concentration of solution in reconstituted vial (ie, either 10 mg\/mL or 20 mg\/mL); add withdrawn volume to an NS or D5W infusion bag or syringe, ensuring that final concentration of solution is between 0.5 mg\/mL to 4 mg\/mL; if final concentration of solution is greater than 1.5 mg\/mL, label the bag or syringe for administration via central catheter<\/li><li>protect diluted solution from light; no need to cover the infusion chamber or the tubing<\/li><li>administer within 24 hours of dilution<\/li><li>(infusion) infuse over 1 hour; do not administer as an IV bolus injection<\/li><li>do not mix or co-infuse with other medications<\/li><li>an existing IV line should be flushed with NS prior to infusion<\/li><\/ul>"},"10":{"id":"jwcgs10","title":"Monitoring","mono":"<ul><li>CBC<\/li><li>liver function tests (monitor for worsening in patients who develop abnormal liver function tests during therapy)<\/li><li>renal function tests (monitor for worsening in patients who develop abnormal renal function tests during therapy)<\/li><\/ul>"},"11":{"id":"jwcgs11","title":"How Supplied","mono":"<ul><li><b>Mycamine<\/b><br\/>Intravenous Powder for Solution: 50 MG, 100 MG<br\/><\/li><li><b>NovaPlus Mycamine<\/b><br\/>Intravenous Powder for Solution: 50 MG, 100 MG<br\/><\/li><\/ul>"},"13":{"id":"jwcgs13","title":"Clinical Teaching","mono":"<ul><li>May cause headache, skin rash, nausea, vomiting, or diarrhea.<\/li><li>Instruct patient to report signs\/symptoms of renal or liver dysfunction.<\/li><\/ul>"}}}